Phio Pharmaceuticals Corp. (PHIO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.05

From 52W high−58.47%

Volume156449.00

Market cap$11.97M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.05

From 52W high

−58.47%

Volume

156449.00

Market cap

$11.97M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

P/E (TTM)

—

RSI (14)

45.1

MomentumView details →

1D Return

+0.98%

YTD Return

−1.43%

SummaryUpdated Jun 1, 2026

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company founded in 2011 and headquartered in Marlborough, Massachusetts. Originally incorporated as RXi Pharmaceuticals Corporation, the company rebranded to its current name in November 2018. Phio specializes in developing immuno-oncology therapeutics using its proprietary INTASYL platform, which focuses on enhancing the body's immune system to fight cancer through innovative gene regulation techniques.

Ask drillr about Phio Pharmaceuticals Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−102.40%

ROA (TTM)

−90.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+100.00%

FCF YoY

−70.87%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−59.34%

EBITDA YoY

−82.21%

MomentumView details →

1D Return

+0.98%

YTD Return

−1.43%

1Y Return

−50.00%

RSI (14)

45.1

vs 50D SMA

−2.90%

vs 200D SMA

−7.29%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

15.87x

Quick Ratio

15.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.36

EPS Surprise

0.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.36

Avg Surprise (4Q)

4.11%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.90M

Op. CF (TTM)

−12.20M

Next earningsNov 12, 2026 →

Latest newsMore news →

Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.62d ago

Similar companies

Aspire Biopharma Holdings, Inc.ASBP BioLineRx Ltd.BLRX Kiora Pharmaceuticals, Inc.KPRX Anebulo Pharmaceuticals, Inc.ANEB CytoMed Therapeutics LimitedGDTC Medicus Pharma Ltd. Common StockMDCX Find similar companies →

Latest newsMore news →

Phio Pharmaceuticals Corp. announced a key development milestone for PH-762, submitting a filing to the FDA to support the next stage of clinical development in cutaneous squamous cell carcinoma.6d ago Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.62d ago